Liraglutide Injection Shortage: Victoza Supply Limited While Saxenda Remains Available
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports ongoing supply challenges for Liraglutide injections, specifically affecting Victoza, while other versions remain available for patients.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Liraglutide.
What's in Shortage
Liraglutide injection, a medication used in the therapeutic category of Endocrinology and Metabolism, is currently listed on the FDA drug shortage database. The shortage specifically impacts certain presentations of the medication, including the brand name Victoza. The dosage form affected is the 6 mg/1 mL injection.
This shortage was first posted on July 18, 2023, and was most recently updated on February 1, 2026.
Which Manufacturers Are Affected
Novo Nordisk, Inc. is the primary manufacturer for these products. The availability status varies by specific product and NDC number:
- Victoza (Liraglutide) Injection, 6 mg/1 mL (NDC 0169-4060-12 and 0169-4060-13): Limited Availability. The estimated duration for this shortage is currently to be determined (TBD).
- Saxenda (Liraglutide) Injection, 6 mg/1 mL (NDC 0169-2800-15): Available.
- Liraglutide Injection, 6 mg/1 mL (NDC 0480-3667-22 and 0480-3667-20): Available (Distributed by Teva).
Patients or healthcare providers seeking more information can contact Novo Nordisk, Inc. at 833-493-4689.
Why There's a Shortage
The FDA source data does not provide a specific reason for the limited availability of Victoza at this time.
What Patients Should Do
If you are currently prescribed Victoza or another form of Liraglutide, please consider the following steps:
- Consult your healthcare provider: Discuss your treatment plan and any concerns regarding medication availability. Do not make changes to your medication regimen without professional medical guidance.
- Speak with your pharmacist: Your pharmacist can provide the most current information on local stock levels and potential fulfillment timelines.
- Contact the manufacturer: You may reach out to Novo Nordisk at 833-493-4689 for updates on supply status.
Source
Information provided by the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.